Edgewise Therapeutics(US:EWTX) Seeking Alpha·2026-01-13 19:05Company Overview - Edgewise Therapeutics is a biopharmaceutical company focused on muscle diseases, developing novel orally active drugs for conditions such as muscular dystrophy, serious cardiac issues, and metabolic diseases [2] - The company leverages its expertise in muscle physiology to create first-in-class therapeutic agents [2] Recent Developments - In 2025, Edgewise Therapeutics completed enrollment in the pivotal Becker study for its drug sevasemten, with data readout expected by the end of the year [3] - The Duchenne program has shown promising results, with a decrease in the rate of decline in patients previously treated with steroids and gene therapy, and data collection on a subset of 60 patients is anticipated later this year [4] - Positive data has also been reported for the cardiovascular asset, referred to as 7500 [4]